10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than ...
8 September 2021 - Researchers and policy makers in the US are exploring the implementation of health technology assessment and value ...
26 August 2021 - Report will be subject of Midwest CEPAC meeting in April 2022; Draft Scoping Document open to public ...
25 August 2021 - Report will be subject of CTAF meeting in April 2022; draft scoping document open to public comment ...
24 August 2021 - Patients initiating therapy in real world dataset had less frequent baseline attack rates than rates from clinical ...
18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...
17 August 2021 - Given uncertainty about safety data on oral JAK inhibitors for other indications, a narrow majority of the ...
5 August 2021 - Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net ...
22 July 2021 - Public comment period now open until 18 August 2021; requests to make oral comment during public meeting ...
16 July 2021 - Biogen officials defended the company's Alzheimer's drug and criticised ICER's cost effectiveness report today at a meeting ...
9 July 2021 - Evidence demonstrates the JAK inhibitors abrocitinib and upadacitinib are effective treatments for atopic dermatitis, but safety concerns ...
2 July 2021 - The controversial approval last month by the FDA of Aduhelm (aducanumab) for patients with early-stage Alzheimer’s disease ...
30 June 2021 - Report will be subject of New England CEPAC meeting in January 2022; draft scoping document open ...
30 June 2021 - Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, ...
19 June 2021 - The Institute for Clinical and Economic Review is an independent organisation that reviews drugs and devices with ...